Complications of spinal cord stimulation and peripheral nerve stimulation techniques:a review of the literature by Eldabe, Sam et al.
 
 
Complications of spinal cord stimulation and
peripheral nerve stimulation techniques
Eldabe, Sam; Buchser, Eric; Duarte, Rui
DOI:
10.1093/pm/pnv025
License:
None: All rights reserved
Document Version
Peer reviewed version
Citation for published version (Harvard):
Eldabe, S, Buchser, E & Duarte, R 2016, 'Complications of spinal cord stimulation and peripheral nerve
stimulation techniques: a review of the literature', Pain Medicine, vol. 17, no. 2, pp. 325–336.
https://doi.org/10.1093/pm/pnv025
Link to publication on Research at Birmingham portal
Publisher Rights Statement:
Checked for eligibility: 22/03/2016. This is a pre-copyedited, author-produced PDF of an article accepted for publication in Pain Medicine
following peer review. The version of record for 'Sam Eldabe, Eric Buchser, Rui V. Duarte
Pain Med (2016) 17 (2): 325-336 DOI: http://dx.doi.org/10.1093/pm/pnv025 First published online: 14 December 2015 (12 pages)' is
available online at: http://painmedicine.oxfordjournals.org/content/17/2/325.article-info
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 01. Feb. 2019
1 
 
 
Complications of spinal cord stimulation and peripheral nerve stimulation techniques: 
A review of the literature 
Sam Eldabe, MB ChB, FCRA, FFPMRCA
1
  Eric Buchser MD, DEAA
2
  Rui V. Duarte, PhD
3
 
1. Department of Pain and Anesthesia, The James Cook University Hospital, 
Middlesbrough, UK 
2. Anaesthesia and Pain Management Department, EHC-Hôpital de Morges, Morges, 
Switzerland 
3. College of Medical and Dental Sciences, University of Birmingham, Birmingham, 
UK 
 
Corresponding author: Rui V. Duarte. College of Medical and Dental Sciences, University of 
Birmingham, Room 124, Murray Learning Centre, Birmingham B15 2TT, UK 
Email: r.duarte@bham.ac.uk; Telephone: +44 (0) 121 414 7784 
 
Funding sources: None of the authors had any direct or indirect funding in support of this 
study. 
 
Running title: Complications of neurostimulation techniques: a review 
  
2 
 
 
ABSTRACT 
Objective: Spinal cord and peripheral neurostimulation techniques have been practiced since 
1967 for the relief of pain and some techniques are also used for improvement in organ 
function. Neuromodulation has recognised complications, although very rarely do these cause 
long term morbidity. The aim of this article is to present a review of complications observed 
in patients treated with neurostimulation techniques. 
Methods: A review of the major recent publications in the literature on the subjects of spinal 
cord, occipital, sacral and peripheral nerve field stimulation was conducted. 
Results: The incidence of complications reported varies from 30% to 40% of patients affected 
by one or more complications. Adverse events can be subdivided into hardware related 
complications and biological complications. The commonest hardware related complication 
is lead migration. Other lead related complications such as failure or fracture have also been 
reported. Common biological complications include infection and pain over the implant. 
Serious biological complications such as dural puncture headache and neurological damage 
are rarely observed. 
Conclusions: Spinal cord and peripheral neurostimulation techniques are safe and reversible 
therapies. Hardware related complications are more commonly observed than biological 
complications. Serious adverse events such as neurological damage are rare. 
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INTRODUCTION 
The electrical stimulation of the dorsal columns of the spinal cord to induce pain relief was 
first used in humans in 1967 [1].  Despite incomplete understanding of the mechanism of 
action, spinal cord stimulation (SCS) has become increasingly popular and its efficacy has 
been documented in neuropathic pain (level B) [2] as well as ischemic pain, whether due to 
peripheral vascular [3] or coronary artery disease [4]. Studies of SCS have shown that the 
therapy significantly improves the health related quality of life (HRQoL) of users [5]. 
 
A health economic assessment of SCS for the management of chronic neuropathic pain has 
shown the therapy to be cost-effective [6]. The Incremental Cost Effectiveness Ratio (ICER) 
calculated over a 15 years horizon was below £20,000 per quality adjusted life year (QALY) 
[6].  The cost of complications, which is included in the cost of the therapy, has been derived 
from the patient cohort of the PROCESS study and is estimated at an average of £576 per 
patient (SD of £1320) [7]. 
 
The complications of SCS are numerous and incidences of 30% to 40% have been reported in 
multiple studies [8-10]. Hardware-related problems such as lead failure and migration are 
more common than biological complications such as infection, pain, and wound breakdown 
[11, 12]. Infection is one of the major complications of SCS with incidences of 3.4% to 10%, 
and is a common cause for removal of the device and failure of therapy [13, 14].  A review 
has recommended an 18% budgetary allocation average per patient per annum for the 
maintenance of the therapy including complication management [13]. It is important to note 
that in device based therapies, the experience of the implanter impacts significantly on the 
rate of complications. This has been successfully demonstrated in the case of cardioverter 
defibrillator and total hip replacement [15]. 
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The UK National Institute for Health and Care Excellence conclude in their Health 
Technology Appraisal of the therapy that among a total of 403 implanted patients across all 
trials examined, four (1%) device removals were required as a result of infection [16]. Across 
trials, the percentage of implantations requiring surgery to resolve a device-related 
complication, including device removals, ranged from 0% to 38%, which may be due to 
differences in follow- up periods, populations or clinical settings. 
The aim of this review of the literature is to describe the rates of complications observed in 
spinal cord stimulation (SCS), occipital nerve stimulation (ONS), sacral nerve stimulation 
(SNS) and peripheral nerve field stimulation (PNFS). 
 
METHODS 
A review of studies that reported complications associated with the use of SCS, ONS, SNS 
and PNFS was conducted. We searched PubMed, Embase, Cochrane Library and Scopus up 
to December 2014. A combination of MeSH/Thesaurus terms and free-text terms was 
employed, including spinal cord stimulation, occipital nerve stimulation, sacral nerve 
stimulation, peripheral nerve field stimulation, complications, adverse events and side effects. 
The search was restricted to articles published in English. A hand-search of the reference lists 
of studies meeting the inclusion criteria was also performed. 
 
Complications were stratified into the following categories: 
1. Hardware related complications: the commonest being lead related complications such as 
lead migration or fracture, extension related complication, disconnection or misconnection 
and Implantable Pulse Generator (IPG) related complications such a battery depletion, 
flipping and recharging difficulties. 
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2. Biological complications: the commonest of which were infections, deep and superficial, 
the development of haematoma or seroma over the device or more commonly pain over the 
implanted hardware. Less frequent biological complications include dural puncture related 
headaches and the more serious nerve damage including spinal cord injury and paralysis [17]. 
3. Programming or therapy related complications: including loss of paraesthesia and painful 
or unpleasant paraesthesia. These are less threatening and can usually be addressed through 
programming, although on rare occasions can result in device removal due to therapy failure. 
 
HARDWARE RELATED COMPLICATIONS 
Lead Migration 
Lead migration is by far the commonest complication of spinal and peripheral nerve 
stimulation. Peripheral lead migrations have been reported at rates as high as 100% in a case 
series of ONS at 3 years and 60% at the end of 1 year [18] and in 12 of 51 subjects (24%) in 
the ONSTIM study of ONS [19]. In both ONS studies, the leads were secured to fascia and 
positioned at the C1 level. In the ONSTIM study the lead extension was placed with circular 
coils, creating strain-relief loops but this was not employed consistently. The authors 
recommended the use of a strain-relief loop and preference for abdominal to buttock IPG 
positioning to study implanters when a number of lead migrations were reported. 
For mainstream SCS in the hands of experienced implanters a lower incidence is accepted as 
standard. In SCS, the leads are placed in the epidural space in the spine near the region that 
supplies nerves to the painful area. Most reviews do not differentiate between vertical 
(cranio-caudal) and lateral (horizontal) lead migration. In a 20-year literature review of the 
therapy Cameron reported 361 lead migrations in 2753 patients giving an overall rate of 
13.2% [20]. For the studies included in the review, the leads had been positioned either at the 
thoracic or cervical level, but it is not clear if there were differences in the lead migration 
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rates based on lead positioning. In an assessment of 18 studies of SCS in failed back surgery 
syndrome (FBSS) and 8 studies of SCS use in complex regional pain syndrome (CRPS) 
Taylor and colleagues report 20% and 27% respectively in lead related complications [21, 
22]. No breakdown is described of the incidence of fracture and migration. In a review of 410 
patients over a 22-year period Kumar et al report lead migrations in 88 patients (21.4%) of 
which 40 were repositioned and 48 were replaced [23]. The displacement of leads was twice 
higher in the cervical region as compared with lower dorsal placements with the authors 
considering this to be due to mobility of the cervical spine. In a more recent retrospective 
review of 707 patients with a mean follow-up of 3 years and 5 months (range: 3 months to 7 
years), Mekhail et al report an initial lead migration rate of 0.7% during the trial period but a 
subsequent 119 cases of 527 (22.6%) developing lead migration [13]. The authors do not 
elaborate on the numbers of patients requiring revisions. Turner et al reviewed 22 studies of 
SCS; they did not report a rate of lead migration but instead reported a 23.1% rate of 
stimulator revision for reasons other than battery change with a median value of 21.5% and a 
range of 0-80% [11]. In their discussion the authors acknowledge that the majority of these 
occurrences would be related to lead migration, however it is not possible to estimate how 
many of these events were related to lead malfunction instead of migration. In the PROCESS 
study, at 24 months 9 events of lead migrations had occurred in 6 out of 42 patients (14%) 
with all six patients requiring surgery to reposition the leads [24]. In an earlier randomised 
controlled trial (RCT) comparing SCS to reoperation, North and co-authors report that 3/33 
(9%) of patients required lead revision due to migration or malposition [25]. It is important to 
note that the patients in this study received mostly surgical plate leads. These are known to be 
associated with lower migration rates compared to the more commonly used cylindrical 
percutaneous leads [26, 27]. Two RCT’s have recently evaluated SCS in patients with painful 
diabetic neuropathy (DN) [28, 29]. In both studies, the leads were positioned at the thoracic 
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level and anchored to the fascia. Lead migration was observed in one patient (2.5%) in the de 
Vos et al study [28]. It is not clear if lead migration was observed in the Slangen et al trial as 
only two serious adverse events were reported [29]. The authors mention that the 
complication rate in this study was comparable to that reported in the literature. 
For sacral nerve stimulation, the electrode tip is placed near the sacral nerve. In a review of 7 
RCTs and 47 case reports for SNS therapy in functional urinary bladder stimulation, 
Brazzelli et al conclude that lead migration in this therapy occurs in 16% of patients despite 
the use of tined leads [30]. 
For PNFS the leads are placed next to one of the peripheral nerves. In the largest case series 
reporting on the use of PNFS for pain relief, Sator-Katzenschlager [31] and Verrills [32] 
report rates of lead migration of 13% and 2% respectively. The leads were sutured to the deep 
fascia but from the studies, it is unclear the level at which the leads were placed. The large 
difference between both studies may well relate to the multicentre nature of the first study 
compared to the second, which reports a single centre practice and a different definition of 
migration. Indeed when a clinically significant definition of lead migration was adopted, only 
three of 143 patients (2.1%) required surgical revision [33]. This latest SCS retrospective 
review may well reflect improvement in anchoring technology over the last decade. 
In conclusion lead migration remains the most common complication of spinal and peripheral 
nerve stimulation. Although paraesthesia coverage loss due to lead migration can be 
recaptured by reprogramming, the majority of the instances of major lead migration require 
minor reoperation to relocate the lead to its original position and most will incur the cost of a 
new lead [34]. Lead migration rates vary greatly between studies, with some quoting figures 
as high as 60-100%, but the majority quoting figures of 10-25% for spinal cord stimulation. 
This discrepancy can be explained by varying implanter experience, different definitions of 
“migration”, differing clinical context of the therapy, and differing clinical practices. Lead 
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migrations following surgical paddle lead implantation is less common than with 
percutaneous cylindrical leads and that location of the lead in the spine may influence the rate 
of migration, with higher rates occurring where the lead is implanted in a highly mobile area 
of the spine [34]. The impact of the recent improvements in hardware design on the incidence 
of lead migration remains unclear. Table 1 summarises the lead migration incidence quoted 
by various studies. 
Table 1. Lead migration rates for SCS, SNS, ONS and PNFS 
Publication Therapy 
type 
N Migration 
rate % 
Publication Type 
Cameron 2004 [20] SCS 2753 13.2% Review article 
Turner 2004 [35] SCS 830 23.1% Systematic review 
North 2005 [25] SCS 45 9% RCT 
Taylor 2005 [22] SCS 112 27% Systematic review 
Taylor 2006 [21] SCS 66 20% Systematic review 
Kumar 2006 [23] SCS 410 21.4% Retrospective Analysis 
Kumar 2008 [24] SCS 42 14% RCT 
Mekhail 2011 [13] SCS 527 22.6% Retrospective Analysis 
Gazelka 2014 [33] SCS 143 2.1% Retrospective Review 
de Vos 2014 [28] SCS 40 2.5% RCT 
Total SCS 4968 Range 2.1-27% 
Mean 15.49% 
95% CI 9.21-
21.77% 
 
Brazzelli 2006 [30] SNS 785 16% Systematic review 
Schwedt 2007 [18]  ONS 15 60-100% Retrospective Analysis 
Paemeleire 2010 [36] ONS 44 30% Retrospective Analysis 
Saper 2011 [19]  ONS 51 24% RCT 
Sator-Katzenschlager 
2010 [31] 
PNFS 111 13% Retrospective Analysis 
Verrills 2011 [32] PNFS 100 2% Retrospective Analysis 
Confidence intervals are calculated at 95% level 
9 
 
 
 
Lead fracture and malfunction 
Most studies report rates for either lead fracture, malfunction or general hardware 
malfunction. In the PROCESS study the rates are reported as lead or extension fractures, 
however the latter are very rare [24]. A total of 4 events in 3 out of 42 patients (7%) with 
only 1 requiring a surgical revision (2%) were observed [24]. A review identified 250 cases 
of lead breakage out of 2753 cases, an incidence of 9.1% [20]. In his review of 707 cases 
Mekhail and colleagues report lead connection failure occurring in 50 cases (9.5%) and lead 
breakage in 33 cases (6%) [13]. Kumar et al report 24 fractured electrodes out of 410 cases 
(5.9%) all of which were replaced satisfactorily [23]. The usual site of fracture was distal to 
the fixation point to the deep fascia where the lead enters the spinal canal [23]. Turner et al 
report on 20 studies of SCS with a mean incidence of equipment failure across studies of 
10.2% and a median figure of 6.5% and a range of 0-40% [35]. No events related with lead 
fracture or malfunctions were reported in the de Vos RCT of SCS in diabetic neuropathy [28] 
while it was unclear if these events occurred in the Slangen et al study [29]. Paemeleire et al 
report on 44 patients implanted with ONS [36]. The authors note that revision was needed in 
about 30% of patients because of technical problems, which included lead fracture, 
dislocation and connector current leakage. Saper et al report one case of lead fracture at the 
C1 level in 51 cases in the ONSTIM study (2%) [19]. Brazzelli and co-authors report no 
cases of lead fracture in their review of SNS [30]. Table 2 summarises the incidence of lead 
migration in various studies of neuromodulation techniques. 
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Table 2. Lead fracture and malfunction rates for SCS, ONS and PNFS 
Publication Therapy 
type 
N Fracture rate % Publication Type 
Cameron 2004 [20] SCS 2753 9.1% Review article 
Turner 2004 [35] SCS 830 10.2% Systematic review 
Kumar 2006 [23] SCS 410 5.9% Retrospective 
Analysis 
Kumar 2008 [24] SCS 42 7% RCT 
Mekhail 2011 [13] SCS 527 6% Retrospective 
Analysis 
de Vos 2014 [28] SCS 40 0% RCT 
Total SCS 4602 Range 0-10.2% 
Mean 6.37% 
95% CI 2.63-10.10% 
 
Schwedt 2007 [18] ONS 15 0% Retrospective 
Analysis 
Saper 2011 [19] ONS 51 2% RCT 
Sator-
Katzenschlager 
2010 [31] 
PNFS 111 5% Retrospective 
Analysis 
Verrills 2011 [32] PNFS 100 2% Retrospective 
Analysis 
Confidence intervals are calculated at 95% level 
 
Battery failure 
The battery of an IPG is located within the device, when it is depleted, replacement requires 
repeated operation. When a battery requires replacement before the expected date 
(determined by the parameters being used by the patient), it is considered a battery failure. 
Battery failure occurred in 32 (1.7%) of 1900 cases examined by Cameron, although in 22 of 
32 cases battery failure occurred after more than 3 years [20]. Turner et al reported much 
higher equipment failure rates of 10.2%, however this figure did not relate to battery failure 
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specifically but included all hardware failure [35]. Neither the Mekhail et al nor Kumar et al 
studies report on premature battery failure [13, 23]. No premature battery failures were 
reported as part of the PROCESS, North et al, de Vos et al or Slangen et al studies [24, 25, 
28, 29]. No reports of battery replacement are available for ONS or SNS. 
Premature battery depletion is a rare occurrence and shorter than expected lifespan have 
mostly non-technical causes, particularly when the manufacturer’s instructions are properly 
followed.  The current consumption depends on physiological factors (distance to the spinal 
cord), anatomical location (stimulation intensity usually smaller in the cervical region) and 
technical aspects such as the number of active contacts (increased current drain), the current 
intensity and the stimulation patterns.  The latter has become a serious clinical concern as the 
new stimulation modes (high density, burst, high frequency) all have requirements that are 
several orders of magnitude higher than conventional stimulation.  In concrete terms, the new 
modes of stimulation cannot be provided without batteries that can be recharged, and will 
have to do so every day in most cases. 
Rechargeable batteries have been available for a relatively short time and the experience with 
these devices is limited both by the duration use and the paucity of the data available.  
Rechargeable IPG’s have limited lifespans that can vary with manufacturers, but are usually 
9 years or more.  Though potentially more effective and versatile, rechargeable batteries 
require a higher level of patient understanding and awareness.  Some of the early devices 
could not recover after extended period of depletion, a problem that has been largely 
addressed and solved in the newer generation.  Though most depleted rechargeable 
generators can now be revived, the rebooting procedures may need the help of a trained 
technician.  Recharging capabilities, which was initially perceived as a clinical advantage, 
has not always lived up to patient’s expectations as the inconvenience of recharging has 
turned out to be a burden rather than a facility with some patients.  From the cost 
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effectiveness standpoint, clinical as well as modelling studies have suggested that the 
implantation of a rechargeable system is indicated mainly when a cell-driven device last for 
less than approximately 4 years (6; 37).  Theoretically, as the need for battery change is 
decreased, the number of surgical complications of these procedures should be minimised.  
To the best of our knowledge however there is currently no data and we can only speculate. 
Another potentially unpleasant effect of recharging the battery is a heating sensation that is 
felt over the stimulation during the process.  In the more extreme (and rare) cases recharging 
has to be made in multiple sequences in order to avoid excessive discomfort. 
 
BIOLOGICAL COMPLICATIONS 
Pain related to device components 
Patients implanted with neuromodulation devices often report pains related to the site of 
device components such as pain around the IPG site or over the lead anchor site or lead 
extension junctions. In SCS studies the incidence is variable, for example Kumar et al report 
an incidence of 12% (5 of 42 patients) in the PROCESS study with one patient requiring 
reoperation [24]. This high incidence may however relate to the large size IPG used in the 
study - Synergy™ (Medtronic MN, USA).  Kumar et al, observed an incidence of discomfort 
over the IPG of 1.2% (5/410) [23]. The RCT by North did not report on device related 
discomfort [25]. Two patients (5%) experienced pain over the IPG in the RCT by de Vos et al 
[28]. It is unclear if this was observed in the Slangen et al RCT [29]. Mekhail et al reported 
pain at the generator site in 86 (12%) of 707 patients [13]. Cameron reports 24 cases of 
device related discomfort out of a total of 2753 (0.9%) [20].  Turner and co-authors found a 
higher incidence with a mean of 5.8% of patients across 20 studies reporting pain over the 
implant with a median value of 0% and a range of 0-40% [35]. In ONS, Saper et al report 2 
cases of pain over the IPG site and one case of burning pain over lead/extension site; a total 
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of 6% [19]. By contrast Paemeleire reports no cases of pain over the implant site [36]. This 
complication appears to be far more common in SNS. Brazzelli and collegues report a 25% 
incidence of pain over the lead or IPG site [30]. This may well relate to the location of the 
lead and IPG implant in the presacral and buttock area where subcutaneous fat may be denser 
than in the anterior abdominal wall, where most SCS devices are implanted. Pain at the IPG 
site according to where it was positioned is not commonly reported and it is not possible to 
determine if some implant sites are associated with more pain than others, however the IPG 
site selection may significantly influence patient satisfaction due to pain in the IPG site. 
Table 3 summarises the rates of implant-related pain observed. 
 
Table 3. Rates of implant related pain for SCS, SNS and ONS 
Publication Therapy 
type 
N Pain over 
Implant % 
Publication Type 
Cameron 2004 [20] SCS 2753 0.9% Review article 
Turner 2004 [35] SCS 830 5.8% Systematic review 
Kumar 2006 [23] SCS 410 1.2% Retrospective 
Analysis 
Kumar 2008 [24] SCS 42 12% RCT 
Mekhail 2011 [13] SCS 707 12% Retrospective 
Analysis 
de Vos 2014 [28] SCS 40 5% RCT 
Total SCS 4782 Range 0.9-
12% 
Mean 6.15% 
95% CI 0.97-
11.33% 
 
Brazzelli 2006 [30] SNS 653 25% Systematic review 
Saper 2011 [19] ONS 51 6% RCT 
Confidence intervals are calculated at 95% level 
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Wound Infection (Superficial and Deep) and wound breakdown 
Infection is one of the major complications of SCS, with incidences of 4% to 10%, and is a 
common cause for explantation of the device. This incidence is higher than the 2% to 5% rate 
associated with any surgery in the USA [13].  Kumar et al report 14 (3.4%) patients 
experienced infection, 4 of which resolved with antibiotics, whereas the other 10 required 
removal of the hardware and subsequent reinstallation [23].  In the PROCESS study 4/42 
(10%) patients suffered wound infections, with two of those patients requiring surgery [24].  
Mekhail et al report a total of 32 (4.5%) patients with documented infections, of which 22 
cases had deep infections (20 had IPG pocket infections and 2 had lead track infections) [13]. 
The remaining 10 cases had superficial infections limited to the skin and subcutaneous tissues 
at the site of electrode entry over the spine. None of the patients with superficial infections 
had abscess, while 18 of the patients with deep tissue infections had documented abscesses. 
There was only 1 case of epidural infection without any evidence of abscess. This case was 
confirmed by a positive culture that was obtained during explantation surgery, from the 
epidural area. No infections were documented in any of the 707 SCS trials. No statistically 
significant difference was discovered between the various indications of SCS (rates varying 
from 0-6.3%) neither was there a significant difference in infection rates between diabetics 
and non-diabetics [13]. In contrast, relatively low incidences of infection in patients with 
peripheral vascular disease and visceral pain were observed. North and colleagues report two 
cases of infection (6%) one requiring device removal with the other treated with antibiotics 
[25]. Turner et al observed rates of superficial and deep infections averaging 4.5% and 0.1% 
respectively with median values of 4% and 0% and ranges of 0-12% and 0-1% [35]. Cameron 
reports 100 infections in 2972 implants a rate of 3.4% [20]. In a recent series of 53 SCS 
systems implanted in predominantly cancer patients the infection rate was 3.4% and was not 
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higher in cancer than non-cancer patients [38]. One infection during trial stimulation was 
observed in the de Vos SCS RCT for diabetic neuropathy [28]. This infection was resolved 
and followed by a permanent SCS implant. In the other RCT for SCS in diabetic neuropathy 
one patient contracted an infection of the SCS system six weeks post implantation requiring 
antibiotic treatment and system removal [29]. In ONS trials similar rates are described by 
Saper et al (4%) and Paemeleire et al (4.5%) [19, 36]. In SNS, Brazzelli and colleagues found 
wound problem rates of 7% and infection rates of 5% [30]. 
In a study reviewing 114 cases of infection Follett et al reported that 48% of the cases were 
due to Staphylococcus and 3% were due to Pseudomonas [39]. The remaining cases of 
infection were unknown/not reported (24%), showed no growth (18%), or were positive for 
multiple species (6%). Many studies have shown the generator pocket site to be the most 
common location of infection. Follett’s review found 54% of the infections to be in the 
generator pocket. The SCS leads were infected 17% of the time, the lumbar incision site 
(8%), multiple sites (14%), and other/not reported (8%). Potential risk factors for infection or 
poor wound healing included diabetes, debilitated status, malnutrition, extremely thin body 
habitus, obesity, autoimmune disorder, corticosteroid use, decubitus ulcers, pre-existing 
infection, poor hygiene, urinary or faecal incontinence, and malabsorption syndrome [39]. 
The last resort treatment for an SCS infection is complete removal of the system and 
treatment with intravenous antibiotics. If the infection is confined to the generator site, one 
may only remove the generator and treat with antibiotics, leaving the leads in place. 
However, this may make it more difficult to eliminate the infection and often requires 
subsequent lead removal [39]. Eradication of infection without device removal or with partial 
device removal has been associated with lower success rates and higher relapse rates, which 
explains the high rates observed for total device explantation (82%) in comparison with 
partial device explantation (12%) and no explantation (4%) [39]. Both septic (MRSA) and 
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aseptic meningitis have been reported after SCS. There is a further case report of paralysis 
after epidural and intradural abscess formation at lead tip; despite lead explant and abscess 
excision the patient was left with an incomplete recovery [40]. 
Infection prevention techniques include administration of prophylactic antibiotics, adequate 
skin preparation, meticulous attention to sterile techniques in the operating room, and 
adequate wound haemostasis [39]. Table 4 summarises the rate of infection reported in the 
various studies. 
 
Skin Erosion 
Skin erosion of leads or hardware is an uncommon complication of spinal cord stimulation. 
Overall Cameron reports an incidence of skin erosion of 0.2% [20]. This is in contrast with 
subcutaneous nerve field stimulation where Verrills and colleagues report an incidence of 7% 
of hardware erosion in 100 cases [32]. 
 
Device Removal 
There are many reasons for device removal including persistent or overwhelming infection, 
therapy failure, and persistent pain over hardware and skin erosion. Device removal is not 
reported in all SCS studies.  Slangen et al report one patient (4.5%) that had the SCS system 
removed following infection [29]. The review by Turner et al report device removal 
incidence of 11% with a median figure of 6% and a range of 0-47%, although the authors do 
not elaborate on the causes for device removals [35]. Brazzelli et al note an incidence of 9% 
of device removal in SNS [30]. Verrills et al describe two cases (2%) of hardware failure and 
removal in PNFS [32]. 
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Table 4. Rates of infection for SCS, SNS, ONS and PNFS 
Publication Therapy 
type 
N Infection % Publication Type 
Cameron 2004 [20] SCS 2972 3.4% Review article 
Follett 2004 [38] SCS 114 N/A Retrospective review 
Turner 2004 [35] SCS 830 4.6% Systematic review 
North 2005 [25] SCS 45 6% RCT 
Taylor 2005 [22] SCS 112 6% Systematic review 
Taylor 2006 [21] SCS 66 4% Systematic review 
Kumar 2006 [23] SCS 410 3.4% Retrospective Analysis 
Kumar 2008 [24] SCS 42 10% RCT 
Mekhail 2011 [13] SCS 527 4.5% Retrospective Analysis 
de Vos 2014 [28] SCS 40 2.5% RCT 
Slangen 2014 [29] SCS 22 4.5% RCT 
Total SCS 5180 Range 2.5-10% 
Mean 4.89%  
95% CI 3.38-
6.39% 
 
Brazzelli 2006 [30] SNS 727 5% Systematic review 
Pameleire 2010 [36] ONS 44 4.5% Retrospective Analysis 
Saper 2011 [19] ONS 51 4% RCT 
Sator-Katzenschlager 
2011 [31] 
PNFS 111 6% Retrospective Analysis 
Verrills 2011 [32] PNFS 100 1% Retrospective Analysis 
Confidence intervals are calculated at 95% level 
 
Dural Puncture 
Accidental dural puncture can occur during epidural needle placement in lead positioning. 
This can result in post-dural puncture headache symptoms as well as CSF leak into the 
wound. It has been suggested that risk factors for the development of a dural puncture include 
gender [11.1% female vs. 3.6% male, OR 2.25 (1.07-4.73); p = 0.03], age [11.0% 31-50 years 
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of age vs. 4.2% others, OR 2.21 (1.12-4.36); p = 0.02], previous history of post-dural 
puncture headache [26.4% positive vs. 6.2% negative, OR 4.30 (1.99-9.31); p < 0.01] and 
bevel orientation [16.1% perpendicular vs. 5.7% parallel, OR 2.16 (1.07-4.35); p = 0.03] [41]. 
The incidence of dural puncture has been estimated at 0-0.3% [12, 20]. Patients who 
experience post dural puncture headache may suffer from a positional headache, diplopia, 
tinnitus, neck pain, photophobia, and fluid accumulation at the lead anchoring site during the 
perioperative period. These patients will be unable to perform their activities of daily living 
and are therefore unable to assess the efficacy of an SCS trial [14]. The initial approach is to 
suggest bed rest but if the symptoms persist, the treatment options are either a blood patch or 
surgical exploration [14]. Epidural blood patch has been found to be an effective treatment 
for severe post-dural puncture headache, although its effectiveness is decreased if the dura 
mater puncture is caused by a large bore needle [42]. Surgical closure of the dural perforation 
is a last resort option for leaks that are unresponsive to other therapies [43]. 
 
Neurological Injury 
Neurological injury is by far the most dreaded complication of SCS. This can result from 
direct trauma caused by needle puncture, percutaneous lead placement or during surgery for 
placement of paddle leads. Delayed neurological damage can result from epidural haematoma 
or abscess formation. Epidural haematoma formation following the placement of SCS leads is 
a rare occurrence and has been observed mainly following the insertion of paddle leads 
inserted via direct surgical access. One patient in the Slangen et al RCT developed postdural 
puncture headache following a dural puncture, which was complicated by a lethal subural 
hematoma 3 days after the procedure [29]. In a series of 509 plate electrodes Barolat reported 
1 case of epidural haematoma resulting in paraplegia [17]. In a 20 year review of the 
literature Cameron estimated the risk of epidural haematoma development at 0.3% and 
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paralysis at 0.03% [20]. In a more recent attempt to review the literature for incidence of 
neurological damage following surgical paddle lead implantation, Levy and colleagues report 
111 (0.25%) cases of major neurologic deficit in a sample of 44,587 cases, 61 (0.14%) 
limited motor deficit, 6 cases of autonomic changes (0.013%) 46 cases of sensory deficit 
(0.10%) as well as 21 cases of cerebrospinal fluid leakage due to dural puncture [40]. Sixteen 
epidural hematomas with limited motor deficit are reported in the same series as well as 52 
epidural hematomas with major motor deficit (0.12%) and 15 epidural hematomas without 
motor deficit (0.034%).  Early recognition and treatment of neurological deficit allows 
functional recovery in most cases [44].  Trials studying techniques such as SNS, ONS and 
PNFS have not reported complications related to neurological damage. 
Many of the potential SCS patients are medicated with serotonin reuptake inhibitors, 
acetylsalicylic acid (aspirin), nonsteroidal anti-inflammatory drugs and anticoagulants, all of 
which may increase the risk of post-operative epidural hematomas. Recommendations for 
interventional spine and pain procedures in patients on antiplatelets/anticoagulants are now 
available and should be implemented according to the patient perioperative medication [45]. 
The application of these recommendations can lead to a decrease in the risk of epidural or 
spinal hematoma. Alcohol consumption greater than 10 units a week, multilevel procedure, 
and previous spinal surgery have also been identified as risk factors for developing spinal 
epidural hematoma [46]. 
 
FACTORS AFFECTING THE RATE OF OCCURRENCE OF COMPLICATIONS 
A number of factors may affect the rate of occurrence of complications in peripheral 
neuromodulation techniques. 
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Location of the lead 
A differential in the rate of occurrence of lead migration has been observed when the use of 
spinal cord stimulation was examined for differing indications. For example locating the lead 
in the relatively immobile thoracic spine for indications such as refractory angina was 
associated with lower lead migrations rates. In a review of the subject Taylor et al report a 
combined rate of lead migration or fracture of 7.8% (10 out of 128 patients) [4]. This is much 
lower than the rates the same author observed for CRPS (20%) and FBSS (27%) [21, 22]. We 
may conclude that the position of the lead in a non-mobile area of the spine has a limiting 
effect on the rate of migrations.  However we must note that time since implant, anchoring 
technique and hardware improvements may act as confounding factors. 
There is no study that compares different techniques of implantation and/or anchoring 
electrodes. Anchoring device preferences and techniques are based on personal experience or 
theoretical concepts that make intuitive sense, but have not been actually tested in vivo. What 
most implanters would agree with is that the provision of strain relief loops in electrodes as 
well as extensions seems to improve the stability of the stimulating portion of the electrode. 
 
Epidural vs. extra-spinal position of the lead 
While one would expect an epidural position of the lead to impart a stabilising effect on the 
lead used for SCS, the figures do not seem to support this conclusion.  For example in the 
case of PNFS where rates of lead migration and fracture are lower than, or similar to, those 
reported for SCS in general. Sator-Katzenschlager et al report a lead migration rate of 13% 
for PNFS, and an overall rate of complications of 24% which is similar to SCS reported rates 
in general [31]. This contrasts with higher rates reported for techniques such as ONS where 
Paemeleire et al [36] reports 14/44 patients (31.8%) requiring lead replacement and Schwedt 
reported rates of lead migration of 24% within three months of stimulator implantation and 
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100% at 3-year follow-up [18, 47]. These rates do not take into consideration the experience 
of the operator performing the technique. Bias in reporting of complications in retrospective 
case series cannot be ruled out. 
 
Relative novelty of a technique and operating surgeon’s experience 
Other implant disciplines have demonstrated a clear link between the level of experience of 
the operating surgeon and the rate of occurrence of complications related to the implant 
procedure [15, 48, 49]. This seems to be the case in the world of neuromodulation, where 
early work on ONS by Schwedt [18] was associated with a much higher rate of complications 
relative to the later reports by Paemeleire [36] and Saper [19]. 
In the field of spinal cord stimulation a recent cohort study by Turner et al utilised non-
experienced implanters and consequently reported higher complication rates as well as the 
occurrence of rare life threatening complications [50]. Furthermore, early SCS work by 
Andersen [51] in SCS for refractory angina treatment reported an incidence of lead migration 
of 23% versus a more recently reported incidence of 7.8% by Taylor et al [5]. We can 
therefore suggest that novel techniques in spinal and peripheral nerve stimulation may be 
associated with a higher rate of complications, particularly lead related complications, and 
that as surgeons gain experience in a particular implant technique the complication rates 
reduce over time. This seems to be the case with SCS of the dorsal root ganglion, a newly 
developed technique for the management of chronic neuropathic pain. A recent report with 1-
year follow-up of 32 patients in which this intervention was used, observed a higher overall 
incidence of adverse events when compared with SCS [52]. Forty-three adverse events 
considered by the authors not to be related with the SCS system were observed, of which the 
most common were CSF leak with associated headache (8.5%), and infection (8.5%). A field 
safety action notice has been issued by the manufacturer of SCS for DRG advising how to 
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remove a lead [53]. According to the manufacturer as of May 2014, over 2000 DRG leads 
had been implanted and there had been 10 reports of lead breakage during attempted lead 
removal which resulted in lead fragments. 
In an initial feasibility study investigating stimulation of the multifidus muscle for the 
management of low back pain, 5 of the 26 implanted patients decided to withdraw from the 
study due to lead dislocation in the first 60 days of treatment [54]. The authors used SCS 
systems and leads from different manufacturers for this feasibility study. A new system and 
leads have now been developed purposefully for the stimulation of the multifidus muscle. 
Studies are ongoing to investigate this new technique for the management of low back pain. 
 
Hardware appropriateness for the procedure 
Hardware for peripheral and spinal cord stimulation techniques has evolved significantly over 
the last 4 decades. While we continue to await the introduction of custom made hardware for 
particular techniques such as ONS and PNFS, such custom made hardware is already in 
existence for SCS and SNS. In SCS the hardware has evolved from monopolar leads through 
quadripolar leads to the current state of the art 16 contact leads. Early reports of 
complications, particularly the need for lead replacement, show a statistically significant 
lower rate in patients with quadripolar leads (11%) than in those with monopolar electrodes 
(45%) (p <0.003) [51]. As there was no difference in the frequency of electrode migration 
between the two types of electrodes, proper paraesthesia coverage was most often recaptured 
by reprogramming with the multipolar leads [51]. North et al reported SCS treatment in 62 
patients with chronic pain [55]. They found that surgical revision was necessary in 23% of 
the cases in which simple bipolar leads were placed to obtain optimal paraesthesia coverage. 
Surgical revision, however, was required in only 16% of those cases with multichannel 
devices. The drive to increase the number of contacts on an electrode array is the idea that 
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reprogrammation can restore appropriate stimulation if the electrode migrates in a cranio-
caudal direction.  This is largely supported by common sense rather than by clinical studies.  
There is no credible data to suggest the rate of revision has been minimised by the increased 
number of contacts, though the speculations are convincing.  In addition, it is generally 
believed that the reimbursement strategy (payment per contact) that prevailed in the USA for 
a number of years has strongly encouraged the production and the use of electrodes carrying 
an increasing number of contacts. 
Finally the introduction of rechargeable pulse generators may well reduce the need for battery 
replacements in a population of neurostimulation patients, particularly those indications 
requiring high current consumption such as peripheral arterial disease [56]. However this fact 
remains to be established in the long term. 
 
Reporting of Complications 
The reporting of incidences of complications in neuromodulation studies remains variable.  
This relates to the varying denominator in the formula used for percentage incidence 
calculations. While the majority of studies report the incidence of complications in 
percentage some studies consider the total number of subjects included in the study [54, 57] 
as the denominator while other consider the subjects trialled, implanted or in some cases the 
total number of adverse events [58] has been used to express an incidence of adverse events. 
A more helpful format for the reader would be to report adverse events and complications in 
a table format showing the type and adverse events and the number of occurrences in the 
study as well as number of patients affected by the event. This would be followed by a 
percentage expressing a clear denominator /N figure on the table. While dividing by the 
number of subjects intended to receive the therapy seems at first glance the most appropriate 
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way forward, one needs to consider that some adverse events are inapplicable to some of the 
subjects, such as pocket pain, which is unlikely in subjects who have had a failed trial. 
In the United States, the American Society of Anesthesiologists Closed Claims Project 
database collets malpractice insurance organisation claim files. The database consists of 
standardised summaries of each case and includes a detailed narrative summary of each 
claim. This database allows identification of major safety concerns, patterns of injury and 
strategies for prevention to improve patient safety by anaesthesiologists and may provide 
further data to that available in the current literature. 
 
CONCLUSION 
Spinal cord and peripheral nerve stimulation therapies are safe and reversible therapies. 
These effective therapeutic techniques may result in a range of minor complications. 
Hardware related complications are more common than biological complications with lead 
related complications most frequent. Biological complications include commoner 
complications such as infection and pain over the implant. Serious adverse events such as 
neurological damage are uncommon. 
The rate of development of complications is governed by factors such as the lead position in 
the spine or periphery, the experience of the surgeon and the availability of custom made 
equipment for the technique. 
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